Researchers from Nationwide Children’s Hospital have published in JAMA Neurology results from the first four patients treated in the first clinical trial of systemic delivery of micro-dystrophin gene therapy in children with Duchenne muscular dystrophy (DMD) — and initial findings suggest that the therapy can provide functional improvement that is greater than that observed under the standard of care.
- COVID-19 lockdown reduced mental health, sleep, exercise
- Coating implants with ‘artificial bone’ to prevent inflammation
- COVID-19 anxiety linked to body image issues
- Medical minds meet to develop novel treatment for one patient’s immune system defect
- Report calls for easing access, improving home health for older adults